Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice.
Reprod Toxicol
; 104: 134-142, 2021 09.
Article
in English
| MEDLINE | ID: covidwho-1331182
ABSTRACT
AZD1222 (ChAdOx1 nCoV-19) is a COVID-19 vaccine that is not yet licensed for use during pregnancy. To support the inclusion of pregnant and breastfeeding people in AZD1222 clinical studies, a non-clinical developmental and reproductive toxicity study was performed to evaluate its effects on fertility and reproductive processes of female CD-1 mice during the embryofetal development phase, and postnatal outcomes during the littering phase. Immunogenicity assessments were also made in dams, fetuses, and pups. There were no vaccine-related unscheduled deaths throughout the study. Furthermore, there were no vaccine-related effects on female reproduction, fetal or pup survival, fetal external, visceral, or skeletal findings, pup physical development, and no abnormal gross pathology findings in pups or dams. Antibody responses raised in dams were maintained throughout gestation and postnatal periods, and seroconversion in fetuses and pups indicate placental and lactational transfer of immunoglobulins. Together with clinical data from non-pregnant people, these results support the inclusion of pregnant and breastfeeding people in AZD1222 clinical studies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vaccination
/
Immunogenicity, Vaccine
/
COVID-19 Vaccines
/
Antibodies, Viral
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Pregnancy
Language:
English
Journal:
Reprod Toxicol
Journal subject:
Embryology
/
Reproductive Medicine
/
Toxicology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS